Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

EarningsVyeptiPositive

AI Analysis

Summary

Lundbeck reported H1 2026 total revenue growth of +16% CER to DKK 13,588 million, driven by strong performance of Vyepti and focused commercial execution in the U.S. and Europe.

Financial Highlights

Revenue

DKK 13,588 million

Importance:4/10

Sentiment:

0.70

earningsrevenue_growthcommercial_executionH1_2026

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on August 19, 2026 6:03 AM

Read Original